Pharmacokinetic interaction between itraconazole and rifampin in Yucatan miniature pigs

被引:17
作者
Kaltenbach, G [1 ]
Leveque, D [1 ]
Peter, JD [1 ]
Salmon, J [1 ]
Elkhaili, H [1 ]
Cavalier, A [1 ]
Salmon, Y [1 ]
Monteil, H [1 ]
Jehl, F [1 ]
机构
[1] INST BACTERIOL,LAB PHARMACOCINET,F-67000 STRASBOURG,FRANCE
关键词
D O I
10.1128/AAC.40.9.2043
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The objective of this study was to examine the effects of rifampin on itraconazole pharmacokinetics, at steady state, in three Yucatan miniature pigs, Daily for 3 weeks, the pigs received 200 mg of itraconazole orally at the beginning of each meal, and for the following 2 weeks they received itraconazole orally combined with intravenous administration of rifampin at 10 mg/kg/day, Coadministration of rifampin resulted in an Id-fold decrease in the maximum concentration of itraconazole in serum, from 113.0 (standard deviation [SD] 17.2) to 6.2 (SD, 3.9) ng/ml and a 22-fold decrease in the area under the concentration-time curve, from 1,652.7 (SD, 297.7) to 75.6 (SD, 30.0) ng . h/ml, The active metabolite of itraconazole, hydroxyitraconazole, was undetectable, This study demonstrates that rifampin affects itraconazole kinetics considerably at steady state in this miniature-pig model, probably by inducing hepatic metabolism of itraconazole.
引用
收藏
页码:2043 / 2046
页数:4
相关论文
共 21 条
[1]   CLINICAL PHARMACOKINETICS OF RIFAMPICIN [J].
ACOCELLA, G .
CLINICAL PHARMACOKINETICS, 1978, 3 (02) :108-127
[2]   INDUCTION OF FLUCONAZOLE METABOLISM BY RIFAMPIN - INVIVO STUDY IN HUMANS [J].
APSELOFF, G ;
HILLIGOSS, DM ;
GARDNER, MJ ;
HENRY, EB ;
INSKEEP, PB ;
GERBER, N ;
LAZAR, JD .
JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 31 (04) :358-361
[3]   UPDATE ON RIFAMPIN DRUG-INTERACTIONS [J].
BACIEWICZ, AM ;
SELF, TH ;
BEKEMEYER, WB .
ARCHIVES OF INTERNAL MEDICINE, 1987, 147 (03) :565-568
[4]   FOOD INTERACTION AND STEADY-STATE PHARMACOKINETICS OF ITRACONAZOLE CAPSULES IN HEALTHY MALE-VOLUNTEERS [J].
BARONE, JA ;
KOH, JG ;
BIERMAN, RH ;
COLAIZZI, JL ;
SWANSON, KA ;
GAFFAR, MC ;
MOSKOVITZ, BL ;
MECHLINSKI, W ;
VANDEVELDE, V .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (04) :778-784
[5]   ITRACONAZOLE AND ANTI-TUBERCULOSIS DRUGS [J].
BLOMLEY, M ;
TEARE, EL ;
DEBELDER, A ;
THWAY, Y ;
WESTON, M .
LANCET, 1990, 336 (8725) :1255-1255
[6]   UPDATE ON RIFAMPIN DRUG-INTERACTIONS .2. [J].
BORCHERDING, SM ;
BACIEWICZ, AM ;
SELF, TH .
ARCHIVES OF INTERNAL MEDICINE, 1992, 152 (04) :711-716
[7]   DISPOSITION OF KETOCONAZOLE, AN ORAL ANTIFUNGAL, IN HUMANS [J].
BRASS, C ;
GALGIANI, JN ;
BLASCHKE, TF ;
DEFELICE, R ;
OREILLY, RA ;
STEVENS, DA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1982, 21 (01) :151-158
[8]   PHARMACOKINETIC STUDY OF THE INTERACTION BETWEEN RIFAMPICIN AND KETOCONAZOLE [J].
DOBLE, N ;
SHAW, R ;
ROWLANDHILL, C ;
LUSH, M ;
WARNOCK, DW ;
KEAL, EE .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1988, 21 (05) :633-635
[9]   COADMINISTRATION OF RIFAMPIN AND ITRACONAZOLE LEADS TO UNDETECTABLE LEVELS OF SERUM ITRACONAZOLE [J].
DRAYTON, J ;
DICKINSON, G ;
RINALDI, MG .
CLINICAL INFECTIOUS DISEASES, 1994, 18 (02) :266-266
[10]   ITRACONAZOLE - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC USE IN SUPERFICIAL AND SYSTEMIC MYCOSES [J].
GRANT, SM ;
CLISSOLD, SP .
DRUGS, 1989, 37 (03) :310-344